This comparative guide examines the leading GLP-1 analogs available for research—semaglutide, tirzepatide, and retatrutide—highlighting their structural features, receptor activities, and research applications. Understanding the differences between these molecules is essential for selecting the appropriate tool for your research.
Semaglutide is a selective GLP-1 receptor agonist with a fatty acid moiety that promotes albumin binding and extends half-life. It is available in once-weekly subcutaneous and once-daily oral formulations. Semaglutide has demonstrated significant efficacy for glycemic control and weight loss, with cardiovascular benefits established in the SELECT trial. In the first quarter of 2026, semaglutide's global sales were approximately US$8.277 billion[reference:113].
Tirzepatide is a dual GLP-1/GIP receptor agonist with a fatty acid moiety for extended half-life. It has shown superior efficacy compared to selective GLP-1 agonists in clinical trials. Tirzepatide contributed US$12.822 billion in revenue to Eli Lilly in the first quarter of 2026[reference:114]. The dual agonism provides complementary benefits, resulting in enhanced glycemic control and weight loss.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. This multi-target approach is designed to provide additional metabolic benefits beyond those of dual agonists. Early clinical data suggest that retatrutide may offer even greater weight loss than existing therapies, making it a promising candidate for obesity treatment.
For researchers, these analogs provide tools for studying incretin biology, investigating multi-target approaches, and developing next-generation metabolic therapeutics. At PeptideHub, we offer these and other GLP-1 analogs for research applications, with high purity and full analytical documentation.